Portal de Periódicos da CAPES

Long‐term survival after autologous peripheral blood stem cell transplantation in two patients with malignant rhabdoid tumor of the kidney

2009; Wiley; Volume: 52; Issue: 7 Linguagem: Inglês

10.1002/pbc.21958

1545-5017

Yuhki Koga, Akinobu Matsuzaki, Aiko Suminoe, Miho Hatano, Yusuke Saito, Yoshiaki Kinoshita, Tatsuro Tajiri, Tomoaki Taguchi, Kenichi Kohashi, Yoshinao Oda, Masazumi Tsuneyoshi, Toshiro Hara,

Prenatal Screening and Diagnostics

Abstract A 5‐month‐old male with stage II malignant rhabdoid tumor of the kidney (MRTK) and a 24‐month‐old male with stage III MRTK were treated with surgical resection of tumors and chemotherapy of alternating ICE (ifosfamide, carboplatin, and etoposide) and VDC (vincristine, doxorubicin, and cyclophosphamide), followed by high‐dose chemotherapy using etoposide, carboplatin, and melphalan with autologous hematopoietic stem cell transplantation (SCT). Two patients have been alive without any evidence of disease for 30 and 37 months after diagnosis, respectively, and require no medication. Consolidation with SCT should be further studies for selected patients with high‐risk MRTK. Pediatr Blood Cancer 2009;52:888–890. © 2009 Wiley‐Liss, Inc.